维眸生物科技（浙江）有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma 2023-06-05 08:00
VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye Disease 2022-03-23 08:00
1